First Manhattan
VTGN icon

First Manhattan’s VistaGen Therapeutics VTGN Stock Holding History

First Manhattan’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-333
Closed -$1.71K – 1500
2023
Q4 		$1.71K Buy
+333
New +$1.26K ﹤0.01% 1297

Other funds holding VTGN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

First Manhattan's VTGN Position: Q1 2024 in Review

First Manhattan sold out of VistaGen Therapeutics (VTGN) in Q1 2024, closing a stake of 333 shares — an estimated $1.71K sold.

First Manhattan first reported a position in VTGN in Q4 2023 and held it in 1 quarter. The position peaked at $1.71K in Q4 2023. 42 funds tracked by Wall St. Rank hold VTGN as of Q1 2024.

  • First Manhattan reported no remaining VistaGen Therapeutics position as of Q1 2024 after selling out during the quarter.
  • First Manhattan sold 333 VistaGen Therapeutics shares in Q1 2024, an estimated $1.71K.
  • First Manhattan first reported a position in VistaGen Therapeutics in Q4 2023 and held it in 1 quarter.
  • First Manhattan's VistaGen Therapeutics position peaked at $1.71K in Q4 2023.
  • 42 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2024.

Based on First Manhattan's 13F filing for Q1 2024, filed 15 May 2024.